Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Programm zur Familienplanung nach der Geburt in Ruanda

27. August 2026 aktualisiert von: Kristin Wall, Emory University

Implementierung und Evaluierung eines groß angelegten postpartalen Familienplanungsprogramms in Ruanda

This trial wants to address high unmet need for postpartum family planning (PPFP) in Rwanda. A previous pilot study tested the intervention (informed by formative work with couples/clients, clinic providers, champions, and community health workers), which significantly increased the use of PPFP in government clinics. This study now proposes to use an implementation science framework to test the hypothesis that the proposed PPFP intervention is adaptable to large-scale implementation, cost-effective, and sustainable. This PPFP could dramatically reduce unintended pregnancy and abortion and improve birth spacing and maternal and newborn health.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

In 2017-2018, the study team worked closely with the Rwanda Ministry of Health (MOH) to develop and pilot test a theory-based, multi-level intervention targeting postpartum family planning (PPFP) supply and demand in 4 government health facilities in Kigali, the capital. This innovative PPFP intervention was informed by clients, clinic providers, champions, and Community Health Workers. Long-acting reversible contraceptives (LARC), the intrauterine device (PPIUD) and implant, are fundamental to PPFP programs. LARCs are highly effective and are the only reversible methods that may be safely used in early postpartum period by breastfeeding women. During the pilot, LARC uptake among postpartum women increased significantly (172% for PP implant, 2,687% for PPIUD), PPFP feasibility and acceptability were high among providers and clients, and side-effects were rare.

In this trial, the study team used an implementation science framework to evaluate the effectiveness of different PPFP demand creation strategies and test the hypothesis that our PPFP intervention is adaptable to large-scale implementation, cost-effective, and sustainable. In a Type 2 effectiveness-implementation hybrid study, the study team evaluated facility organizational readiness prior to implementing the PPFP intervention in a clinic randomized trial in 10 high-volume health facilities in Kigali, Rwanda (Aim 1). Adaptability and sustainability within government facilities is a critical aspect of the proposal, and the MOH and other local stakeholders will be engaged from the outset. The study team expected that this project would deliver PPFP counseling to over 21,000 women/couples during the project period. They also evaluated the PPFP intervention effectiveness and implementation processes using RE-AIM (Aim 2). The team hypothesized that the PPFP intervention would significantly increase the number of stakeholders engaged, PPFP providers and promoters, couples/clients receiving information about PPFP (reach), and LARC uptake (effectiveness) comparing intervention versus standard of care. It was expected that PPFP client satisfaction resulted high and side-effects, rare. The independent effectiveness of each demand creation strategy on LARC uptake was estimated. Assessment of measures of PPFP intervention adoption, implementation, and maintenance at the patient-, provider- and stakeholder-level to assess PPFP intervention sustainability was completed by the study team. Finally, this project will evaluate PPFP intervention cost-effectiveness and develop a national costed implementation plan to guide Rwandan MOH decision-making for nationwide roll-out of PPFP services (Aim 3). This trial hypothesizes that the PPFP intervention will be cost-saving relative to standard of care.

This intervention represents an important contribution to the Rwanda Family Planning 2020 goals and the MOH are enthusiastic to see our successful pilot efforts expanded to a larger number of facilities for greater and sustained impact. The new PPFP implementation model is designed to be replicable and expandable to other countries in the region which similarly have high unmet need for PPFP.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

38220

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Kigali Province
      • Kigali, Kigali Province, Ruanda
        • Project San Francisco, Kigali

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Eligible PPFP promoters will be government facility providers working in ANC,L&D, IV and/or postpartum services at one of the study facilities.
  • Eligible PPFP providers will be government facility providers working in L&D, and/or family planning services at one of the study facilities.
  • Eligible Happy Client promotors will be postpartum women who received promotions and selected a PPFP method.
  • Eligible nurse/midwife and CHW promotors will be women working as nurses or CHWs at one of the intervention facilities.
  • All women eligible for PPFP services in this study will be at any stage of pregnancy or up to 14 weeks postpartum, and receiving antenatal care (ANC), L&D, IV, or postpartum services at one of the intervention or pilot facilities

Exclusion Criteria:

  • Prisoners

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: PPFP Intervention

The study team will train government clinic staff in ANC, L&D, IV, or postpartum services to promote and provide the PPFP intervention at the selected facilities. Community Health Workers (CHW) and 'Happy Clients' will be trained as PPFP promotional agents. Video-based PPFP promotions will be shown at the intervention facilities. If interested in PPFP, women will be referred to the facility by their CHW.

C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.

The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW.

Kein Eingriff: Standard of Care

Currently, no systematic PPFP training, promotional, or service delivery activities are regularly taking place at the selected facilities. The team will compare the intervention with historical records from the facilities applying intervention and compare

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Numbers of Clinic Directors Engaged
Zeitfenster: Through study completion, an average of 2 years

Number of clinic directors engaged to support implementation of the PPFP intervention. Clinic directors were engaged at the beginning and end of intervention activities in each cluster and as needed, throughout intervention implementation to facilitate study activities until study completion.

Through study completion, an average of 2 years
Number of Nurses Trained to Promote PPFP
Zeitfenster: After completion of a 2-day training session

The number of nurses who complete PPFP intervention session to promote PPFP use

After completion of a 2-day training session
Number of CHWs Trained to Promote PPFP
Zeitfenster: After completion of a 2-day training session

The number of community health workers (CHWs) who complete C4 training session to promote PPFP use

After completion of a 2-day training session
Number of Providers Trained to Provide PPFP
Zeitfenster: After completion of a 2-day training session

Nurses and midwives working in labor and delivery and family planning will attend a 2-day didactic training session. Providers will complete a post-training test consisting of 10 true-or-false questions. Those who do not score at least 80% on the post-training test will be offered re-training after one week.

After completion of a 2-day training session
Number of Providers Certified to Provide PPFP
Zeitfenster: After completion of a 2-day training session

After completing the didactic training, providers will have the opportunity to become certified, by correctly inserting 5 PPIUDs and 5 PP implants under supervision.

After completion of a 2-day training session
Number of Promotions to Pregnant or Postpartum Women/Couples
Zeitfenster: Beginning at the first antenatal care visit up to post-partum week 14 (up to 54 weeks)

The number of one-on-one C4 counseling promotions received by pregnant or postpartum women/couples.

Beginning at the first antenatal care visit up to post-partum week 14 (up to 54 weeks)
Number of PPIUD Insertions
Zeitfenster: Up to postpartum week 14

The number of PPIUDs provided to postpartum women after C4 counseling. PPIUDs may refer to hormonal or copper IUDs.

Up to postpartum week 14
Percentage of Deliveries Followed by PPIUD Insertions
Zeitfenster: Before discharge after delivery (up to 2 days after delivery)

This outcome reports the percentage of deliveries followed by a PPIUD insertion in postpartum women in the Standard of Care (SOC) and C4 Intervention time periods.

Before discharge after delivery (up to 2 days after delivery)
Number of PP Implant Insertions
Zeitfenster: Up to postpartum week 14

The number of PP Implants provided to postpartum women after C4 counseling.

Up to postpartum week 14
Percentage of Deliveries Followed by PP Implant Insertion
Zeitfenster: Before discharge after delivery (up to 2 days after delivery)

This outcome reports the percentage of deliveries followed by a PP Implant insertion in the Standard of Care and C4 Intervention time periods.

Before discharge after delivery (up to 2 days after delivery)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cost-effectiveness/Cost-utility: Couple Years Protection (CYP)
Zeitfenster: Years 2 and 4 of the project period

Cost, in US dollars adjusted for the year of data analysis per CYP

Years 2 and 4 of the project period
Cost-effectiveness/Cost-utility: Cost Per Quality Adjusted Life Years (QALY)
Zeitfenster: Years 2 and 4 of the project period

Cost, in US dollars adjusted for the year of data analysis of cost per QALY saved

Years 2 and 4 of the project period

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Kristin Wall, PhD, Emory University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. August 2022

Primärer Abschluss (Tatsächlich)

30. September 2024

Studienabschluss (Geschätzt)

1. März 2027

Studienanmeldedaten

Zuerst eingereicht

14. September 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. September 2021

Zuerst gepostet (Tatsächlich)

24. September 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • STUDY00002354
  • R01HD101600 (US NIH Stipendium/Vertrag)
  • 2023P006031 (Andere Kennung: Emory IRB)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Individual participant data that underlie the results reported in this article, after deidentification

IPD-Sharing-Zeitrahmen

Immediately following publication, ending 5 years following article publication

IPD-Sharing-Zugriffskriterien

Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the Rwanda National Ethics Committee, to achieve the aims in the approved proposal. Proposals should be directed to kmwall@emory.edu. To gain access, data requestors will need to sign a data access agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .